49
Active Trials
22
Phase 1
16
Phase 2
19
Phase 3
9
Therapeutic Areas
Portfolio Concentration: 133% of active trials in Oncology
Oncology
65 active / 88 total
Solid Tumor (Advanced)
14 active
2 Ph3
17 total since 2015
NSCLC
12 active
5 Ph3
16 total since 2015
Breast Cancer
7 active
4 Ph3
10 total since 2015
SCLC
3 active
1 Ph3
3 total since 2015
Lung Cancer (General)
3 active
3 total since 2015
Prostate Cancer
3 active
3 total since 2015
Gastric Cancer
3 active
2 Ph3
3 total since 2015
Esophageal Cancer
3 active
2 Ph3
3 total since 2015
Hematologic Malignancies
2 active
1 Ph3
4 total since 2015
AML
2 active
4 total since 2015
Bladder Cancer
2 active
1 Ph3
3 total since 2015
Ovarian Cancer
2 active
1 Ph3
3 total since 2015
Endometrial Cancer
2 active
1 Ph3
2 total since 2015
Melanoma
1 active
2 total since 2015
Head and Neck Cancer
1 active
2 total since 2015
Brain Tumor
1 active
1 total since 2015
Cervical Cancer
1 active
1 total since 2015
Non-Hodgkin Lymphoma
1 active
1 total since 2015
Renal Cell Carcinoma
1 active
1 total since 2015
Sarcoma
1 active
1 total since 2015
Neuroendocrine Tumors
0 active
3 total since 2015
Colorectal Cancer
0 active
2 total since 2015
Immunology
2 active / 15 total
Cardiovascular
0 active / 11 total
Metabolic
0 active / 5 total
Pain
0 active / 3 total
Respiratory
0 active / 1 total
Infectious Disease
0 active / 1 total
Urology
0 active / 1 total
Ophthalmology
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)